MedPath

FerruMax Pharmaceuticals, Inc.

🇺🇸United States
Ownership
Private
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:1

Trial Phases

2 Phases

Early Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Early Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

An Exploratory Study to Evaluate FMX-8 to Treat Anemia in CKD

Early Phase 1
Terminated
Conditions
Anemia in Chronic Kidney Disease
Interventions
First Posted Date
2014-08-29
Last Posted Date
2016-02-02
Lead Sponsor
FerruMax Pharmaceuticals, Inc.
Target Recruit Count
2
Registration Number
NCT02228655
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

A Phase 2A Trial of FMX-8 Treatment for Anemia in Patients With ESRD on Hemodialysis HD

Phase 2
Terminated
Conditions
Anemia of Chronic Disease
Interventions
First Posted Date
2013-06-10
Last Posted Date
2015-08-11
Lead Sponsor
FerruMax Pharmaceuticals, Inc.
Target Recruit Count
6
Registration Number
NCT01873534
Locations
🇺🇸

DaVita Arvada Dialysis Center, Arvada, Colorado, United States

🇺🇸

DaVita Minneapolis Dialysis Unit, Minneapolis, Minnesota, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.